UNSPSC 51373319: Aspirin/butalbital/caffeine/codeine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.

UNSPSC 51373319 Aspirin/butalbital/caffeine/codeine is a Commodity code, but recent state and local procurement activity under this code does not align with the code's nominal scope. The three most recent opportunities tagged to this code involve naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products — none of which are aspirin-based combination analgesics. The mismatch suggests either systematic miscoding in state and local procurement systems or that this code is being used as a catch-all for pharmaceutical procurement outside its intended product family. The issuing bodies pursuing pharmaceutical sourcing include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple states (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP, which includes Oregon participants).

Recent opportunities show substantial activity across Florida, Texas, and the upper Midwest. Seminole County issued an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, Florida. The Texas Health and Human Services Commission posted an RFI (HHS0017013, due April 3, 2026) exploring vendor capacity for direct-to-manufacturer prescription programs outside traditional PBM and GPO channels. MMCAP, administered by the Minnesota Department of Administration, issued an RFP (S1070000015802, due March 26, 2026) for generic pharmaceuticals and OTC products across multiple participating states, requiring vendors to supply through three authorized wholesalers with fixed pricing, EDI capability, and compliance with cGMP and DSCSA standards. The code shows little relevant recent activity for the aspirin-based combination product it nominally describes.